Shares of Avanir Pharmaceuticals jumped 10 percent in premarket trading Tuesday after it struck an exclusive deal with Merck & Co., the world's third-largest drugmaker, to promote type 2 diabetes treatments.

Avanir said Monday after markets closed that in October, its sales force will start promoting Merck's Januvia family of products at long-term care facilities in the U. S.

Avanir gets a fixed fee plus an incentive-based payment as part of the multi-year agreement. It didn't provide further details about the agreement.

Jefferies analyst Thomas Wei said in a research note that the deal lasts three years, and Avanir is eligible to receive up to $60 million. He also said that the deal could be extended since Januvia has U. S. patent protection extending at least until 2022.

"We see this co-promotion arrangement as a positive way for (Avanir) to leverage its dedicated sales force at minimal additional cost," Wei wrote, noting that he company recently expanded to 80 representatives from 54.

That expanded sales force allows Avanir to reach about 50 percent of all nursing homes, Wei said.

The agreement may also help defray some the costs fo Avanir to build out its sales team, Wei said, and the new products will have little impact on their ability to promote Avanir's Nuedexta. That drug treats pseudobulbar affect, a condition associated with brain disease or injury that involves involuntary emotional outbursts like laughing or crying.

Shares of Avanir Pharmaceuticals Inc. climbed 45 cents to $4.95 in premarket trading. The stock has traded between $2.07 and $5.09 over the past year.

About News.net

Publishing Services International Limited (PSIL) is the publisher and operator of a worldwide network of online news sites dedicated to delivering fair, accurate and relevant reporting from a variety of the world’s most trusted sources – from the biggest cities to the smallest towns.

We deliver positive and powerful messages to our readers, providing up‑to‑the‑second news that matters to the individual.

Our promise is to serve communities and individuals worldwide, delivering information that hasn’t always been available to them. We will give them back a voice – a voice that’s empowering because it is theirs – and provide a platform to communicate between themselves and the world.

We believe people are not just generic demographics; they are individuals with their own preferences and curiosities. We are about understanding these individuals, listening to them, and serving them.

We are the new pioneering spirit of news – we’re not talking to everyone, we’re talking with every one.

If you want your news, your voice, your way, on your time – we’ve got news for you.

 

FAQs

Email

If you have any questions or concerns please email us on support@news.net

Phone

  • Australia, Toll Free 1-800-983-421
  • Hong Kong, Toll Free 800-906-187
  • Singapore, Toll Free 800-852-3871
  • USA/Canada, Toll Free 1-800-830-4132

Advertise With Us

Interested in being awesome?
Contact us by email or phone.

Cancel